Abstract

The molecular interactions underlying regulation of the immune response take place in a nanoscale gap between T cells and antigen-presenting cells, termed the immunological synapse. If these interactions are regulated appropriately, the host is defended against a wide range of pathogens and deranged host cells. If these interactions are disregulated, the host is susceptible to pathogens or tumor escape at one extreme and autoimmunity at the other. Strategies targeting the synapse have helped to establish immunotherapy as a mainstream element in cancer treatment. This Masters’ primer will cover the basics of the immunological synapse and some of the applications to tumor immunology.

Introduction

T-cell–dependent immune responses protect the host from cancer (1, 2), but also participate in destructive autoimmunity (3, 4). T-cell receptor (TCR) engagement leads to suppression of T-cell locomotion, formation of a specialized junction, and T-cell polarization (5–7). This combination of a specialized junction, cell polarization, and positional stability bears a striking similarity to the classical synapse of the nervous system (8, 9). T cells can also integrate signals through the antigen receptor during migration, and we have referred to this type of mobile, antigen recognition structure as a kinapse (10). The immunological synapse or kinapse integrates three broad categories of receptors: antigen (TCR), adhesion, and costimulatory/checkpoint. The organization of these receptors in the interface affects how they function in a way that cannot be predicted without this spatial and temporal information. The textbook picture of antigen recognition across an approximately 15-nm gap between a T cell and an antigen-presenting cell (APC) provides the justification for why the immune system needs a synapse or kinapse (11). Adhesion molecules, identified first by function with blocking antibodies and then by expression cloning, provide the energy needed to pull cells together, allowing sustained antigen recognition and precise execution of effector functions (12). Finally, costimulatory and checkpoint receptors alter the functional outcome of immunological synapse formation substantially and can also influence the synapse–kinapse balance (13, 14). To date, immunotherapies targeting checkpoint receptors have provided the most promise (15).
Top-down analysis of T cell–APC pairs using immunofluorescence (16) and bottom-up approaches of applying purified molecules to substrates have both contributed to our understanding of the immunological synapse. Reconstitution methods based on fluid-supported lipid bilayers (SLB), in which the purified molecules are combined in a laterally mobile form, have been effective in recreating the organization of the immunological synapse formed with live T cells (16, 17). The canonical organization of the immune synapse is a bull’s eye structure with a central TCR–MHC interaction cluster surrounded by a ring of LFA-1–ICAM-1 adhesion and a distal ring that includes the transmembrane tyrosine phosphatase CD45 (18, 19). Kupfer referred to these radially symmetric compartments as supramolecular activation clusters (SMAC; Fig. 1; ref. 16). The segregation of TCR–MHC interactions from LFA-1–ICAM-1 interactions was a confirmation of the working model formulated by Springer in 1990 that, based on their sizes, the TCR–MHC interactions would need to segregate laterally from the LFA-1–ICAM-1 interactions (12). This is a stereotypical response of helper, cytotoxic, and regulatory T cells (20–23). The SMACs of a stable synapse correspond to polarized compartments in a kinase (24). T cells and dendritic cells (DC) have a more complex organization of similar compartments, perhaps due to the intricate topology of DCs (25, 26). We first consider the three categories of receptors that are organized in the synapse and then how they are coalesced into a functional synapse or kinapse.

**T-cell antigen receptor**

TCR interaction with MHC–peptide complexes controls the specificity of the immune response and the source of antigens in both cellular and humoral responses. TCR genes undergo rearrangement similar to that of antibody genes (27). T cells with subunits encoded by the \( \alpha \) and \( \beta \) genes make up the classical diverse repertoire of naïve T cells that can respond to pathogens and tumors. T cells with subunits encoded by the \( \gamma \) and \( \delta \) genes include specialized cells that are not MHC restricted. The complete TCR on the cell surface is composed of two highly diversified antigen recognition subunits that are noncovalent complex with nonpolymorphic CD3e–CD3\( \gamma \), CD3e–CD3\( \gamma \), and CD3\( \varepsilon \)–CD3\( \varepsilon \) dimers (28). The entire complex has 10 immunotyrosine activation motifs (ITAM) with paired tyrosine residues that, when phosphorylated, can recruit the nonreceptor tyrosine kinase zeta-associated protein of 70 kDa (ZAP-70; Fig. 2; refs. 29, 30).

Although it was recognized by 1975 that cell surface–expressed gene products of the highly polymorphic MHC were...
required to "restrict" T-cell recognition of antigen (31), the full molecular picture of how antigenic peptides bound to MHC was not clear until the crystal structure of an MHC molecule was solved in 1987 (32). There are two distinct types of MHC that control antigen recognition—one set of genes for cytotoxic T cells (CTL) that bind endogenously synthesized cytoplasmic peptides generated by the proteasome (class I), and a distinct set of genes for helper T (Th) cells that bind exogenous antigens taken into the cell by endocytosis (class II). The process of cross-presentation or cross-dressing allows specialized APCs needed for T-cell priming to present exogenous antigens through the class I pathway, which is likely critical for anticancer cellular immunity (33). MHC class II molecules can also engage in signaling (Fig. 2; ref. 34). Other MHC-like molecules present nonpeptide antigenic structures. These include CD1d presentation of glycolipids to invariant natural killer (NK) T cells and MR1 presentation of bacterial metabolites to mucosa-associated invariant T cells (MAIT). These innate-like T cells may have utility in immune response to tumors (35).

Conventional αβ T cells are marked by different coreceptors, CD8 and CD4 (36). CD8 binds to nonpolymorphic elements of MHC class I, and CD4 to that of MHC class II. In T-cell development, thymocytes rearrange TCR genes and test receptors for interaction with self-peptides on MHC. Strong interactions lead to apoptosis or, for a limited number of clones, the generation of actively suppressive thymic regulatory T cells (Treg), which are important in tumor immunology as their formation of immunological synapses can suppress antitumor responses in part by destabilizing T-effector immunological synapses (37–40). Differences in signaling between conventional αβ T cells and Tregs offer therapeutic opportunities to push the balance toward regulation in autoimmunity and toward responsiveness in cancer therapy (23, 41). A weaker recognition process is required for thymocyte survival, and this is thought to bias the TCR repertoire toward recognition of MHC with either CD4 or CD8 (42). This weak self-recognition is thought to set the stage for foreign peptide recognition by providing the T cell with weak recognition of the peptide flanking, polymorphic α-helices of the MHC proteins, and also provides survival signals to mature T cells. It is still debated whether the germline-encoded TCRs are evolutionarily biased to recognize MHC molecules in a certain preferred orientation, or if the germline TCR repertoire has an antibody-like lack of bias and entirely learns to recognize MHC molecules in the thymus (43, 44).

In a tumor context, antigen recognition can enhance or inhibit responses. The classical tumor-infiltrating lymphocyte (TIL) is a CD8 CTL that can directly kill tumor cells, and the infiltration of tumors by CD8 T cells correlates with better outcome for some tumors (2). APCs in tumors can include CD11c+ cells with characteristics of DCs (45). Cancer vaccines can promote expansion and differentiation of T cells with antitumor specificity in a therapeutic setting (46).
T-cell specificity can also be engineered through introduction of chimeric antigen receptors into patient cells in adoptive immunotherapy (47).

**Adhesion receptors**

Adhesion molecules are critical for sensitive antigen recognition required for tumor rejection (48). Strategies based on immunizing mice with CTL lines followed by selection for mAbs that block killing led to the discovery of lymphocyte function–associated antigen-1 (now CD11a/CD18, but often referred to as LFA-1), LFA-2 (now CD2), and LFA-3 (now CD58; Fig. 2; ref. 49).

CD2 and CD58 define a heterophilic adhesion receptor pair (50). CD2 and CD58 are members of the immunoglobulin (Ig) superfamily and are similar in size to the TCR and MHC–peptide complex, suggesting that CD2 may cooperate very closely with the TCR (12, 51). CD2 and CD58 are members of the signaling lymphocyte activation molecule (SLAM) family. Most other SLAM family members are homophilic (they mediate adhesion by binding between products of the same gene) that interact through their cytoplasmic domain with SLAM-associated protein (SAP), which links to the tyrosine kinase Fyn (52). SLAM family members are required for particular interactions between thymocytes in the development of certain specialized T-cell lineages and for early T-cell–B-cell interactions required for germinal center formation (53).

LFA-1 is a heterodimer with a unique α subunit that shares a β subunit with three other cell-surface heterodimers, each of which has an α subunit with a distinct expression pattern. Functional screening for mAbs that block LFA-1-dependent aggregation after immunization with B cells from LFA-1–deficient patients identified the first LFA-1 ligand, intercellular adhesion molecule-1 (ICAM-1 or CD54; ref. 54). LFA-1 is a member of the integrin family, and ICAM-1 is a member of the Ig superfamily. The intercellular link formed by the interaction of LFA-1 with ICAM-1 is much longer than that with the TCR, and it was suggested that the TCR–MHC and LFA-1–ICAM-1 interactions would need to segregate laterally in the interface, the first prediction on the structure of the immunological synapse (12). ICAM-2, a second ligand for LFA-1 that was cloned from an endothelial cell library, is also an Ig superfamily member (55). ICAM-3 was defined by functional blocking in a screen in which ICAM-1 and ICAM-2 were blocked (56). T cells express other adhesion molecules including additional integrins (57). Integrin ligands are expressed on all nucleated cells and can be further induced, in the case of ICAM-1, by exposure of stromal cells to inflammatory cytokines, including TNF, IL-1β, or IFNγ (58). A complication of the therapeutic use of anti-LFA-1 mAbs is that LFA-1 is important for interactions with endothelial cells (59), which are important for optimal localization of cells, in addition to immunological synapse formation. Anti–LFA-1 mAbs were approved for treatment of psoriasis, but the therapeutic window between reduction of disease and increased vulnerability to infection was too small (60). There are activating Abs to LFA-1, but the affinity of LFA-1 for ICAMs is optimized to allow rapid leukocyte migration, and constitutively active LFA-1 is defective in mediating migration, contraindicating LFA-1 affinity enhancement as a therapeutic strategy (61).

Although adhesion molecules are diverse in structure, both integrins and the SLAM family signal through the Src family kinase Fyn rather than Lck, which is the primary partner for antigen and costimulatory receptors (62). Another common feature is that both LFA-1 and CD2 engage ligands in the periphery of the immunological synapse, even though the CD2–CD58 interactions are the correct size to colocalize with TCR in the center (Fig. 2; see Supplementary Information in ref. 17).

**Costimulation**

Costimulatory receptors have minimal signaling or adhesive activity on their own, but can enhance adhesion and signaling locally when combined with other stimuli, primarily through the TCR (63, 64). Costimulatory receptors were predicted as a corollary of the clonal selection model, in which T cells must be able to attenuate their responses to harmless foreign proteins from the environment that are not present in the thymus and could drive inappropriate immune responses if not checked by some mechanism for extrathymic tolerance (65). Pathogens or tumors would need to upregulate costimulation to drive a T cell to respond, and incorporation of costimulatory ligands directly into tumor cells has been implemented in tumor vaccines (66). Activation of mature T cells in the absence of costimulation leads to a second round of clonal deletion that protects the host against immune responses to harmless environmental antigens. Jenkins and Schwartz (67) discovered that antigen recognition with suboptimal costimulation could induce a state of nonresponsiveness that they named anergy.

The archetypal costimulator is CD28, which is an Ig superfamily member with a homodimeric structure and a cytoplasmic domain lacking enzymatic activity but containing motifs that recruit and activate Lck and indirectly, protein kinase C (PKC)-δ, an important PKC isoform in T cells that contributes to the activation of NF-κB transcription factors and promotes IL2 production (Fig. 2; ref. 68). The activity of CD28 is dependent upon the upregulation of B7-1 (CD80) and B7-2 (CD86) on APCs and the interaction in an immunological synapse (26). Both CD80 and CD86 are upregulated on DCs by stimulation through maturation signals delivered by Toll-like receptors and inflammatory cytokines (69, 70). This is a critical link between innate and adaptive immunity, and the potential of some tumors to grow without inducing expression of costimulatory ligands may allow them to tolerate tumor-specific T cells.

The inducible T-cell costimulator (ICOS, CD278) is a second Ig superfamily costimulatory system. In contrast with CD28, it is not expressed on naive T cells, but is upregulated following T-cell activation and binds ligand of ICOS (LICOS, CD275; ref. 71). LICOS is expressed prominently on DCs and B cells, but can be induced on stromal cells by inflammatory cytokines. ICOS is critical for germinal center reactions, in which its ability to activate phosphatidylinositol-3-kinase is particularly important (72). In the context of cancer immunotherapy, ICOS costimulation promotes Th17 differentiation in CD4 T cells, which is an effective response mode for some solid tumors (71).
The other large costimulatory receptors are members of the TNF receptor (TNFR) superfamily, including CD27, GITR (CD357), 4-1BB (CD137), and OX40 (CD134). These receptors signal through TNFR-associated factors (TRAF) using K63 ubiquitination to signal through activation of NF-kB2 transcription factors (73, 74). With the exception of CD27, which is constitutively expressed, these costimulatory receptors are induced on conventional T cells in hours to days following initial activation. Therefore, they are involved in effector and memory functions of T cells following the initial expansion phase. These receptors are also constitutively expressed on Tregs, and this perhaps offers an opportunity to modulate negative regulation in the tumor microenvironment (TME). The last set of costimulatory receptors are members of the lectin-like receptor superfamily that pair covalently with DAP10, a disulfide-linked heterodimer containing a sequence motif that allows recruitment of phosphatidylinositol-3-kinase, which contributes to activation of the growth-promoting kinase AKT (75). These receptors, with NKG2D as a prime example, are expressed on CTLs as well as NK cells and promote killing. The counter-receptors for NKG2D are induced by cellular stress and are potentially important in recognition of deranged host cells (69, 76). However, tumor cells proteolytically shed one of the human counter-receptors, MICA, leading to jamming of this system as an escape mechanism (77).

There is evidence for combinations of adhesion and costimulatory ligands generating partial signals that can lead to transient formation of ligand-independent immunological synapses. This has been observed with NKG2D in human (22) and mouse (78) CTLs and recently for CD28 in Th cells (79). In this context, the upregulation of ICAM-1, CD80, and NKG2D ligands such as MICA (human) and Rae-1 (mice) can induce a state of heightened surveillance in inflamed or stressed tissues.

**Checkpoint blockade**

Coinhibitory or checkpoint receptors are a natural complement to the costimulators—they use various negative signaling pathways, often recruiting tyrosine phosphatases, such as SHP-1 and SHP-2, to attenuate tyrosine kinase cascades or other signaling pathways.

One of the best-defined checkpoint inhibitors is cytotoxic T-lymphocyte antigen-4 (CTLA-4, CD152), which is induced rapidly following T-cell activation (80, 81). CTLA-4 has a constitutively active internalization motif in its cytoplasmic domain such that it does not accumulate on the cell surface except when ligated in the synapse or when the Y-based internalization motif is phosphorylated (82). CTLA-4 competes with CD28 for binding to CD80 more potently than for CD86 (83). In Tregs, CTLA-4 is constitutively expressed, and coupling to the endocytic pathway leads to the removal of CD80 and CD86 from APCs, which impairs CD28-dependent responses of other T cells (84). CTLA-4 associates with PKCe in Tregs (Fig. 2; ref. 85). Anti–CTLA-4 mAbs are approved for treatment of melanoma (86). Although CTLA-4–deficient mice suffer from fatal immunopathology (87), there is a significant therapeutic window in which antitumor effects can be achieved with limited toxicity.

Another checkpoint receptor is programmed cell death-1 (PD-1, CD279). PD-1 binds PD-1 ligands 1 and 2 (PD-L1, CD274 and PD-L2, CD273; refs. 88, 89) and is recruited to the immunological synapse in a manner related to MHC–peptide strength and abundance (90, 91). PD-1 recruits SHP-2 tyrosine phosphatase and attenuates early TCR signaling upon ligand binding (Fig. 2; ref. 92). The impact of PD-1 on the stability of the immunological synapse depends upon the context, with destabilization in autoimmune and delayed-type hypersensitivity (93, 94), but stabilization in antiviral responses (95). Stabilization of the immunological synapse in this context results in an immune paralysis in which the T cell cannot respond nor be released to engage other targets. PD-1 is associated with T-cell exhaustion in chronic viral infection, and this mechanism can protect the host from immunopathology related to toxicity of chronic immune responses (96). However, it can be exploited by pathogens and tumors as an evasion mechanism (97). Recently, mAbs to PD-1 have been approved for treatment of melanoma in Japan and the United States; so far, results in melanoma and lung cancer are promising (98). The ability to predict patient response based on information about the tumor is a significant goal of personalized medicine. Trials are in progress to determine if PD-L1 expression on the tumor predicts patient response. PD-1 is expressed on Tregs and suppresses its activity. Thus, blockade of PD-1 may increase Treg function, suggesting a rationale for combining anti–PD-1 with anti–CTLA-4 (99), as the latter suppresses Treg function. Other checkpoint inhibitors include Vista and SIRPα (CD172A; refs. 100, 101).

**Hierarchy of interactions**

Antigen, adhesion, and costimulatory/checkpoint receptors are highly interdependent. LFA-1 activity on T cells is increased by TCR signaling in a process referred to as inside-out signaling (102). This observation leads to a “chicken and egg” problem for initiating TCR signaling in which LFA-1 clearly is important for T-cell sensitivity to antigen (103), yet TCR signaling is necessary for activation of LFA-1. A likely solution involves chemokines in the tissue microenvironment, which stimulate the activity of LFA-1 at the leading edge of T cells and establish a low level of transient LFA-1–dependent adhesion, thus increasing the chances that TCR can detect rare MHC–peptide complexes (104). Once the TCR is triggered, this can further enhance LFA-1 activity and promote formation of an immunologic synapse (105). Increases in LFA-1 affinity are driven by large conformational changes in the heterodimers (Fig. 2; ref. 106). Costimulatory receptor CD28 interacts with ligands in a TCR-dependent fashion, with the critical regulatory step being its low expression on quiescent cells (64), indicating that CD28 only engages its ligand at sites “seeded” by TCR microclusters (MC; ref. 13). One way to consider this is that in the steady state, LFA-1–ICAM-1 interactions allow rapid scanning of APC surfaces for TCR–MHC complexes, whose signaling increases LFA-1–dependent adhesion and generates local MCs, which favors the participation of CD2, CD28, and other small adhesion molecules. Some adhesion molecules and costimulatory receptors cooperate in a process called superagonism. Antibody combinations to CD2 monomer (107) or
single antibodies to CD28 homodimer (108) can induce full T-cell activation in a TCR-dependent manner. The structural basis of these effects is not known, but it appears that in some extreme conditions induced by antibodies, the normal process of TCR induction of adhesion/costimulation can operate backwards. It is not clear if this happens physiologically, but the phenomenon may be useful in a clinical setting if it can be controlled and directed (109).

**TCR microclusters**

When TCRs are ligated by MHC–peptide complexes presented on a cell, e.g., anti-CD3 antibodies on a solid substrate or MHC–peptide complexes and ICAM-1 on a supported planar bilayer, the first structures that can be visualized at the interface are sub-micron TCR clusters that form in an F-actin–dependent manner (110–113). It has been argued that TCRs are preclustered on T cells, but the ligand-induced clusters have a number of distinct characteristics (79, 114). Ligand-induced MCs recruit the src family kinase Lck to the TCR, leading to the phosphorylation of ITAMs and the recruitment and activation of ZAP-70. ZAP-70 phosphorylates the membrane-anchored linker of activated T cells (LAT) that recruits phospholipase Cγ (PLCγ) and facilitates its activation by the inducible T-cell kinase (ITK; ref. 115). PLCγ-mediated generation of diacylglycerol and inositol-1,3,5-trisphosphate leads to the activation of Ras, PKC, and calcium ion effector pathways that can account for transcriptional activation of the T-cell growth and regulatory cytokines such as IL2 (116, 117). TCR can use a module, including the guanine nucleotide exchange factor Vav that activates Notch, to directly control Myc transcription and T-cell proliferation independent of IL2 (118).

Src family kinases Fyn (mentioned in adhesion context) and Lck (dominant kinase downstream of TCR) are regulated by intramolecular interactions. All Src family kinases have a C-terminal tyrosine (Y505 in Lck) that serves as an intramolecular ligand for its own Src homology 2 (SH2) domain. When the SH2 domain is bound to the C-terminal tyrosine in parallel with a second intramolecular interaction of the Src homology 3 (SH3) domain with the polyproline motif between the kinase domain and the SH2 domain, the kinase is locked in an inhibited state. The C-terminal Src kinase (Csk) mediates this phosphorylation when recruited to membrane-anchored Src substrates in the vicinity of the active Src kinase. This negative feedback is counteracted by the transmembrane tyrosine phosphatase CD45. Selective Csk inhibition results in ligand-independent TCR signaling that synergizes with CD28 signals (119). CD45 deficiency results in inhibition of TCR signaling (120). However, CD45 also can reverse activating phosphorylations mediated by Lck and ZAP-70 (121). Interestingly, CD45 is excluded from TCR MCs, and this reduction in CD45 density, based on the large size of its extracellular domain, appears to be important in setting the appropriate local level of phosphatase activity for TCR triggering (113, 122, 123; Fig. 2). Any small adhesion system will generate interactions that exclude CD45, so it is unlikely the CD45 exclusion is sufficient for full TCR signaling, but some level of exclusion appears to be necessary (79, 124).

**Supramolecular activation clusters**

SMACs defined by Kupfer are divided into the central, peripheral, and distal regions, or cSMAC, pSMAC, and dSMAC (Fig. 1). On the basis of analysis of immunological synapse dynamics using the SLB system, dSMAC behaves like the leading lamellipodium of migrating cells in that it undergoes cycles of protrusion and retraction (24). In contrast, pSMAC is rich in LFA-1 and the integrin to cytoskeletal linker talin, defining it as a lamellum, based on an abrupt change in F-actin dynamics and filament decorations compared with the lamellipodium (24, 125). Higher-resolution imaging has forced a revision of Kupfer’s SMAC definitions. First, the active TCR–MHC interactions that lead to signaling in the immunological synapse are concentrated in small MCs that are formed in the dSMAC and move centripetally through the pSMAC to the cSMAC (111, 113, 126). This traversal of the integrin-rich pSMAC by the smaller TCR is possible because the LFA-1–ICAM-1 interaction also begins in MCs in the dSMAC and consolidates into a reticular network with submicron holes in which the TCR–MHC MCs can be fully segregated (127). The LFA-1–ICAM-1 reticulum in the pSMAC is continually moving inward, which allows the central transport of the TCR–MHC MCs (128). Although the immunological synapse can be stable for hours, the dSMAC and pSMAC are highly dynamic structures that are completely renewed every few minutes (24). The second major revision is the structure of the cSMAC. The original cSMAC, as defined by Kupfer, is a TCR–MHC-rich central structure with accumulation of PKC-θ. We now know that the prominent accumulation of PKC-θ is a signature of CD28-dependent costimulation (68). Work with SLB containing only ICAM-1 and activating MHC–peptide complexes revealed a very different cSMAC in which TCR–MHC interactions were highly stabilized and signaling was terminated (17, 113). Further study of bilayers containing ICAM-1, MHC, and CD80 revealed that CD28 and PKC-θ are initially colocalized with TCR in MCs, but on convergence in the cSMAC segregate into a TCR-rich, CD28-deficient zone, in which signaling is terminated, and a TCR-poor, CD28-rich region, in which CD28-PKC-θ-enhanced TCR signaling continues (13, 26). Further analysis of the TCR–MHC-rich signal termination zone in the cSMAC revealed that it is composed of TCR-enriched extracellular microvesicles that bud from the plasma membrane and become trapped in a persistent interaction with the MHC in the SLB (129). Vesicles that bud from the plasma membrane are defined as ectosomes. The budding process is dependent on tumor-susceptibility gene 101 (TSG101), and the buds are arrested by the expression of dominant-negative vacuolar protein sorting 4 (VPS4), implicating the endosomal sorting complexes required for transport (ESCRT) pathway (Fig. 2; ref. 129). This is a property shared with exosomes. In T-cell–B-cell interactions, these TCR-enriched extracellular vesicles are collected by the B cell and moved away from the interface. CD28–CD80 interactions are efficiently sorted away from the bulk of the TCR that is sorted to the extracellular vesicles. Thus, the cSMAC can be divided into two components: the endo-cSMAC, in which TCR and CD28 continue to signal within the synapse, and the exo-cSMAC, composed of TCR-enriched extracellular vesicles. We
have found that the checkpoint receptor PD-1 is highly enriched in the exo-cSMAC. This would suggest that TCR and PD-1 are closely associated and co-sorted or that PD-1 is ubiquitinated. The TCR-enriched vesicles continue to activate signaling in the B cell through engaging surface MHC molecules, and in the case of MHC class II may be relevant to T-cell help delivery as an active form of exo-TCR (129, 130). Studies using the SLB system suggest that all T cells engage in this type of vesicle transfer, opening the possibility that helper, cytotoxic, and regulatory cells may generate exo-TCR in a carrier that can contain other information, including nucleic acids (131). Whether exo-TCR plays a role in the TME is an open question. The modular structure of the immunological synapse thus incorporates a lamellipodium (dSMAC), lamellum (pSMAC), TCR MCs, a sorting domain that can enrich CD28-enhanced TCR signaling complexes (endo-cSMAC), and an extracellular compartment of TCR-enriched extracellular vesicles (exo-cSMAC; Figs. 1 and 2). The exo-cSMAC is a transient compartment that is normally internalized by the APC. When projected into the more complex three-dimensional setting of a T-cell–DC interface, the lamellipodium, lamellum, and multiple endo-cSMACs remain clearly visible at the interface. It is likely that the multifocal close contacts observed in electron microscopy are not MCs, but are multiple, larger endo-cSMAC structures. It has also been observed that the MCs can manifest as small projections that indent the APC surface, rather than moving laterally (132). There is also an LFA-1–dependent actin cloud or lamellum that imparts a more three-dimensional aspect to the actin cytoskeleton, and this structure incorporates a subset of signaling components (133, 134). This raises issues of subsynaptic vesicular components that may also play an important role in signaling (135, 136).

Directed Secretion: A Synaptic Advantage?

A central element of the immunological synapse concept is directed secretion of soluble components into the synaptic cleft (137–139). This is fundamental to models of T-cell help and cell-mediated killing of infected cells or tumor cells. A major assumption has been that orientation of the centrioles and Golgi toward the APC reflects directed secretion. This has been challenged by studies using antibody-mediated capture to determine the orientation of secretion (140). In this case, molecules that move through the highly oriented Golgi can be secreted randomly based on the manner in which secretory vesicles are transported after leaving the Golgi apparatus. For example, IFNy was found to undergo directed secretion from helper T cells, but TNF and chemokines were not directed to the synapse. The TCR can be directly delivered to the synapse in vesicles (141). Cytolytic granules are directly delivered to a secretory domain near the endo-cSMAC compartment (20). Recently, it has been proposed that the centrosome docking at the immunological synapse sets up a de facto primary cilia that enables intraflagellar transport machinery and hedgehog pathway signaling to be implemented in the immunological synapse (142, 143). Despite this high level of specialization, it has been shown that CTLs may operate in a “quick draw” mode and release cytolytic granules at targets without reorienting and docking the centrioles to the synapse (144). NK cells also use more dynamic kinapse in signal integration with tumors, with advantages in the ability to penetrate into the tumor over more stable synaptic interactions (145). However, even for NK cells, converting kinapses into synapses with tumor-targeting antibodies increases the efficiency of killing (146). The potential advantage of synapses is the ability to concentrate the cytolytic components on the target surface. Comparison of synaptic versus kinaptic killing in the context of CD8 versus CD4 cytotoxic T cells in vitro suggests that the advantage of forming a stable synapse is about 3-fold (147, 148). In a murine breast cancer model, anti–CTLA-4 mAbs stimulate motility of activated T cells in the tumor (149), consistent with other evidence that CTLA-4 engagement could stimulate T-cell motility (150). Stabilization of activated T-cell interactions through induction of Rae-1, which binds NKG2D on T cells, was required to decrease tumor growth (149). Antigen recognition processes that lead to stable synapses may be desirable in immunotherapy settings. It will be of great interest to determine the mode of interaction induced by chimeric receptors that combine ITAM and costimulatory signaling in one polypeptide (47), particularly as conventional synapses with B chronic lymphocytic leukemia cells are defective (3). Exocytic trafficking in the synapse is likely to be balanced by endocytic trafficking. One manifestation of endocytic processes is trogocytosis, in which one cell “gnaws” off pieces of another cell. In addition to ESCRT-dependent budding to generate TCR-enriched extracellular vesicles, some fraction of TCRs in the cSMAC regions undergoes internalization and can bring MHC from the APC with it (129, 151). CD8 T cells that capture MHC-peptide from target cells through trogocytosis actually become targets for killing by other CTLs in the culture (152). What controls the ratio of TCR that is transferred to the APCs in extracellular vesicles versus MHC that is captured by the T cell from the APCs is not known, but both processes are readily detectable across a single immunological synapse (129). The consequence of exo-TCR transfer for tumor cells is not known. CTLs have been shown to release TCR-positive vesicles at target cells (153, 154). It is not clear if these are similar to the exo-TCR reported by Choudhuri and colleagues (129) as it is not clear if these exosome-like structures contain recently engaged TCRs or were sorted into these structures without prior ligand engagement through a distinct mechanism of TCR sorting. It may be possible to isolate the vesicles budded from the plasma membrane versus those released from granules and subject these to proteomic analysis and functional testing.

Conclusions

The immunological synapse mode of stable engagement of targets benefits the attack on tumor. One of the challenges is that bona fide tumor antigens are likely to be weaker agonists that may be more dependent on costimulation for stabilization of synapses. Current therapies that target checkpoint receptors are directly manipulating the immunological synapse. Anti–CTLA-4 mAbs may both dis inhibit conventional cytotoxic and helper T cells while taking away one mechanism by which Tregs function to reduce suppression in the draining lymphoid
tissues, among surrounding DCs and in the TME. The impact of PD-1 blockade on T-cell dynamics is determined by the context, including integration of other costimulatory signals. Potential autoimmune toxicity of anti-PD-1 may be offset by the enhancement of Treg function due to blockade of PD-1 on Tregs. Thus, anti–CTLA-4 and anti–PD-1 may be complementary in the TME by offsetting any enhancement of Treg function from PD-1 with blockade by anti–CTLA-4 (99). Antibodies can also have agonistic effects, particularly if Fc binding is intact, leading to additional parameters. TCR-enriched extracellular vesicles, unique structures that share properties with both ectosomes and exosomes, may also have multiple roles in the TME. Further study of the immunological synapse in the TME is needed to appreciate other interactions within and between SMACs to achieve optimal results for immunotherapy.

Acknowledgments

The author thanks members of the Dustin laboratory and collaborators for stimulating discussions and many insights.

Grant Support

M.L. Dustin was supported by NIH grants AI043542 and AI55007, a Principal Research Fellowship from the Wellcome Trust, and a Senior Research Fellowship from the Kennedy Trust for Rheumatology.

Received August 27, 2014; accepted September 18, 2014; published online November 3, 2014.

References

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107–11.

2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Milierci B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960–4.

3. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427–37.

4. Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK, et al. Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med 2012;209:335–52.

5. Kuper A, Singer SJ. The specific interaction of helper T cells and antigen-presenting B cells. IV. Membrane and cytoskeletal reorganizations in the bound T cell as a function of antigen dose. J Exp Med 1989;170:697–713.

6. Dustin ML, Bromley SK, Kari Z, Peterson DA, Unanue ER. Antigen receptor engagement delivers a stop signal to migrating T lymphocytes. Proc Natl Acad Sci U S A 1997;94:3909–13.

7. Kuper A, Singer SJ. The specific interaction of helper T cells and antigen-presenting B cells. IV. Membrane and cytoskeletal reorganizations in the bound T cell as a function of antigen dose. J Exp Med 1989;170:697–713.

8. Dustin ML, Olszowy MW, Holdorf AD, Li J, Bromley S, Desai N, et al. A novel adapter protein orchestrates receptor patterning and cytoskeletal polarity in T cell contacts. Cell 1998;94:667–77.

9. Dustin ML, Colman DR. Neural and immunological synaptic relations. Science 2002;298:785–9.

10. Dustin ML. Cell adhesion molecules and actin cytoskeleton at immunological synapses and kinapses. Curr Opin Cell Biol 2007;19:529–33.

11. Garcia KC, Degano M, Stanfield RL, Brunnmark A, Jackson MR, Peterson PA, et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996;274:209–19.

12. Springer TA. Adhesion receptors of the immune system. Nature 1980;346:425–34.

13. Yokosuka T, Kobayashi W, Sakata-Sogawa K, Takamatsu M, Hamasoto-Tane A, Dustin ML, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. Immunity 2008;29:589–601.

14. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90:297–339.

15. Callahan MK, Wolchok JD. At the bedside: CTLA-4– and PD-1–blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013;94:41–53.

16. Monkas CR, Freiberg BA, Kuper H, Sciaky N, Kuper A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82–6.

17. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221–7.

18. Johnson KG, Bromley SK, Dustin ML, Thomas ML. A supramolecular basis for CD4a tyrosine phosphatase regulation in sustained T cell activation. Proc Natl Acad Sci U S A 2000;97:10138–43.

19. Freiberg BA, Kuper H, Maslanik W, DELI J, Kappler J, Zoller DM, et al. Staging and resetting T cell activation in SMACs. Nat Immunol 2002;3:911–7.

20. Stinchcombe JC, Bassi G, Booth S, Griffiths GM. The immunological synapse of CTL contains a secretory domain and membrane bridges. Immunity 2001;15:751–61.

21. Potter TA, Grebe K, Freiberg B, Kuper A. Formation of supramolecular activation clusters on fresh ex vivo CDB T cells after engagement of the T cell antigen receptor and CD8 by antigen-presenting cells. Proc Natl Acad Sci U S A 2001;98:12024–9.

22. Somersalo K, Anikeeva N, Sims TN, Thomas VK, Strong RK, Spies T, et al. Cytoytic T lymphocytes form an antigen-independent ring junction. J Clin Invest 2004;114:59–77.

23. Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hicklen KL, Brown M, et al. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010;328:372–6.

24. Sims TN, Soos TJ, Xenias HS, Dubin-Thaler B, Hofman JM, Waite JC, et al. Opposing effects of PKCtheta and WASP on symmetry breaking and relocation of the immunological synapse. Cell 2007;129:773–85.

25. Brossard C, Feuillet V, Schmitt A, Randriamampita C, Ramao, Raposo G, et al. Multifocal structure of the T cell–dendritic cell synapse. Eur J Immunol 2005;35:1741–53.

26. Tseng SY, Waite JC, Liu M, Vardhana S, Dustin ML. T cell–dendritic cell immunological synapses contain TCR-dependent CDB2–CDB8 clusters that recruit protein kinase C theta. J Immunol 2008;181:4852–63.

27. Davis MM. Molecular genetics of the T cell receptor beta chain. Annu Rev Immunol 1985;3:537–60.

28. Call ME, Yndol J, Wiedmann M, Wucherpenning KW. The organizing principle in the formation of the T cell receptor–CD3 complex. Cell 2002;111:967–79.

29. Reth M. Antigen receptor tail cue. Nature 1989;338:363–4.

30. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor alpha chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991;64:891–901.

31. Blander RV, Doherty PC, Dunlop MB, Gardner ID, Zinkernagel RM, David CS. Genes required for cytotoxicity against virus-infected target cells in K and D regions of H-2 complex. Nature 1975;254:269–70.

32. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506–12.

33. Wakiw LM, Bevan MJ. Cross-dressed dendritic cells drive memory T-cell activation after viral infection. Nature 2011;471:629–32.
41. Zanin-Zhorov A, Gauld A, Godfrey D, Nadler LM, Glinscher LH. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992;360:266–8.
40. Pilones KA, Anayakkayil J, Demaria S. Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol 2012;2012:720803.
39. Swain SL, Howard M, Kappler J, Marrack P, Watson J, Booth R, et al. Evidence for two distinct classes of murine B cell growth factors with activities in different functional assays. J Exp Med 1983;158:822–35.
38. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, et al. Regulatory T cells inhibit stable contacts between CD4⁺ T cells and dendritic cells in vivo. J Exp Med 2006;203:505–11.
37. Tang G, Adams JY, Tookey AJ, Bl M, File BT, Serra P, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006;7:83–92.
36. Leung MW, Shen S, Lafaille JJ. TCR-dependent differentiation of thymic Foxp3⁺ cells is limited to small clonal sizes. J Exp Med 2009;206:121–31.
35. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013;13:461–7.
34. Zamarin-Zhorov A, Lin J, Scher J, Kumari S, Blair D, Hippen KL, et al. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989;339:61–4.
33. de Fougerolles AR, Springer TA. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 1992;175:185–90.
32. Shimizu Y, van Sesteren GA, Horgan KJ, Shaw S. Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-6, VLA-6) in expression, binding, and costimulation. Immunol Rev 1990;114:109–43.
31. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245–54.
30. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1986;105:321–31.
29. Major EO, Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35–47.
28. Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, et al. Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 2010;115:1572–81.
27. Peterson EJ, Woods ML, Dmowski SA, Derimanov G, Jordan MS, Wu JN, et al. Coupling of the TCR to integrin activation by Slap-130/Fyb. Science 2001;293:2263–5.
26. Martin PJ, Ledbetter JA, Morishita Y, June CH, Beatty PG, Hansen JA. A 44 kldalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol 1986;136:3282–7.
25. Bromley SK, Iaboni A, Davis SJ, Whitty A, Green JM, Shaw AS, et al. The immunological synapse and CD28–CD80 interactions. Nat Immunol 2001;2:1159–66.
24. Babcock SK, Gil RG, Beligrud A, Lafferty KJ. Studies on the two–signal model for T cell activation in vivo. Transplant Proc 1987;19:303–6.
23. McHugh RS, Ahmed SN, Wang YC, Sel KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycoplipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995;92:8059–63.
22. Jencks MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302–19.
21. Kong KF, Yokosuka T, Canino-Balancio AJ, Isakov N, Saito T, Altman A. A motif in the V3 domain of the kinase PKC-theta determines its localization in the immunological synapse and functions in T cells via association with CD28. Nat Immunol 2011;12:1105–12.
20. Inaba K, Milten-Pack M, Inaba M, Haltcock KS, Sakuta H, Azuma M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vivo. J Exp Med 1994;180:1849–60.
19. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;386:384–7.
18. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Holoshitz Y, et al. The inducible costimulator (ICOS) is critical for the development of T(H)17 cells. Sci Transl Med 2010;2:50ra23.
17. Wild MK, Camaggi A, Brown MH, Davies EA, Ohno H, Saito T, et al. Dependence of T cell antigen recognition on the dimensions of an accessory receptor-ligand complex. J Exp Med 1999;190:31–41.
16. Latour S, Foncagalli R, Chen R, Bakowski M, Shi X, Schwartzberg PL, et al. Binding of SAP SH2 domain to Fyn/T H3 domain reveals a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol 2003;5:149–54.
15. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005;201:665–701.
14. Rothlein R, Dustin ML, Martin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 1986;137:1270–4.
13. Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989;339:61–4.
12. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Holoshitz Y, et al. The inducible costimulator (ICOS) is critical for the development of T(H)17 cells. Sci Transl Med 2010;2:50ra23.
75. Giurisato ET, Cellai M, Takai T, Kurosaki T, Fung Y, Longmore GD, et al. Phosphatidylinositol 3-kinase activation is required to form the NKG2D immunological synapse. Mol Cell Biol 2007;27:8583–99.
76. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013;31:413–41.
77. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann H, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 2007;447:482–6.
78. Markiewicz MA, Carayannopoulos LN, Naidenko OV, Matsui K, Burack WR, Wise EL, et al. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005;175:2825–33.
79. Crites TJ, Radhan K, Muller J, Krogsgaard M, Gudla PR, Lockett SJ, et al. TCR Microclusters pre-exist and contain molecules necessary for TCR signal transduction. J Immunol 2014;193:56–67.
80. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459–68.
81. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533–40.
82. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation on the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23–35.
83. Pentcheva-Hoang T, Egen JG, Wojienski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004;21:401–13.
84. Qureshi OS, Zhang Y, Nakamura K, Attridge K, Manzotti C, Schmidt ME, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-exclusive function of CTLA-4. Science 2011;332:600–3.
85. Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, et al. Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function. Nat Immunol 2014;15:465–73.
86. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. Cancer Immunol Res 2012;4:510–7.
87. Dustin ML, Springer TA. T cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;341:619–24.
88. Bachmann MF, McCall-Fairen Z, Schmitz R, Bouchard D, Beach J, Speiser DE, et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 1997;7:549–57.
89. Shimakoa M, Kim M, Cohen EH, Yang W, Astrof N, Peer D, et al. AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci U S A 2006;103:13991–6.
90. Bromley SK, Dustin ML. Stimulation of naive T-cell adhesion and immunological synapse formation by chemokine-dependent- and independent mechanisms. Immunity 2002;10:289–98.
91. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol 2012;24:107–15.
92. Neur C, Hussey RE, Fabbri M, Fox D, Acuto O, Fitzgerald KA, et al. An alternative pathway of T cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 1984;36:897–906.
93. Evans EJ, Esnouf RM, Manso-Sancho R, Gilbert RJ, James JR, Yu C, et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol 2005;6:271–9.
94. Jungr T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 2012;12:317–8.
95. Bunnell SC, Hong DI, Kardon JR, Yamazaki T, McGlade CJ, Barr VA, et al. T-cell receptor ligation induces the formation of dynamically reconfigurable immunological synapses. Science 2005;309:1398–402.
96. Campi G, Varma R, Dustin ML. Actin and agonist MHC-peptide complex-dependent T-cell receptor microclusters as scaffolds for signaling. J Exp Med 2005;202:1031–6.
97. Massmann KD, Campi G, Groves JT, Dustin ML. Altered TCR signaling from geometrically repatterned immunological synapses. Science 2005;310:1191–3.
98. Varma R, Campi G, Yokosuka T, Saito T, Dustin ML. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 2006;25:117–27.
99. Lillemoe BF, Mortelmair MA, Forstner MB, Huppa JB, Groves JT, Davis MM. TCR and Lat are expressed on separate protein islands on T cell membranes and coaggregate during activation. Nat Immunol 2010;11:90–6.
100. Samelson LE, Patel MD, Weissman AM, Harford JB, Klausner RD. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986;46:1083–90.
101. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263–74.
102. Dustin ML, Chan AC. Sensing takes shape in the immune system. Cell 2000;103:283–94.
103. Guy CS, Vignali KM, Temirov J, Bettini ML, Overace AE, Smeltzer M, et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol 2013;14:262–70.
104. Tan YX, Manz BN, Freedman TS, Zhang C, Shokat KM, Weiss A. Inhibition of the kinase Csk in T lymphocytes reveals a requirement for...
actin remodeling in the initiation of full TCR signaling. Nat Immunol 2014;15:186–94.

120. Koretzky GA, Picus J, Thomas ML, Weiss A. Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidylinositol pathway. Nature 1990;346:66–8.

121. Mustelin T, Williams S, Tailor P, Couture C, Zenner G, BURN P, et al. Regulation of the p70s6k tyrosine protein kinase in T cells by the CD45 phosphotyrosine phosphatase. Eur J Immunol 1995;25:942–6.

122. James JR, Vale RD. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 2012;487:84–7.

123. Cordoba SP, Choudhuri K, Zhang H, Bridge M, Basat AB, Dustin ML, et al. The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor. Blood 2013;121:3021–3022.

124. Ires C, Symons A, Michel F, Bakker TR, van der Merwe PA, Acuto O. CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling. Nat Immunol 2003;4:189–97.

125. Yi J, Wu XS, Critts T, Hammer JA 3rd. Actin retrograde flow and actomyosin II arc contraction drive receptor cluster dynamics at the immunological synapse in Jurkat T cells. Mol Biol Cell 2012;23:834–52.

126. Yokosuka T, Sakata-Sogawa K, Kobayashi W, Hiroshima M, Hashimoto-Tane A, Tokunaga M, et al. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat Immunol 2005;6:1253–62.

127. Kaizuka Y, Douglass AD, Varma R, Dustin ML, Vale RD. Mechanisms for segregating T cell receptor and adhesion molecules during immunological synapse formation in Jurkat T cells. Proc Natl Acad Sci U S A 2007;104:20296–301.

128. Hartman NC, Nye JA, Groves JT. Cluster size regulates protein sorting in the immunological synapse. Proc Natl Acad Sci U S A 2009;106:12729–34.

129. Choudhuri K, Lodola J, Roth EW, Tsai J, Gordo S, Wucherpfennig K, et al. Polarized release of T-cell receptor-enriched microvesicles at the immunological synapse. Nature 2014;507:118–23.

130. Dustin ML. What counts in the immunological synapse? Mol Cell 2014;54:255–62.

131. Mitrebrun M, Gutierrez-Vazquez C, Villarroya-Beltri C, Gonzalez S, Sanchez-Cabo F, Gonzalez MA, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Immunity 2004;20:577–86.

132. Dustin ML. What counts in the immunological synapse? Mol Biol Cell 2012;23:834–52.

133. Sage PT, Varghese LM, Martinelli R, Sciuto TE, Kamei M, Dvorak AM, et al. The large ectodomains of CD45 and CD148 regulate their clustering and cell activation. Sci Signal 2011;4:ra66.

134. Beal AM, Anikeeva N, Varma R, Cameron TO, Norris PJ, Dustin ML, et al. Protein kinase C{theta} regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by T. J Immunol 2008;181:4815–24.

135. Beal AM, Anikeeva N, Varma R, Camelio TO, Vasiliev-Shamis G, Norris PJ, et al. Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain. Immunity 2009;31:338–42.

136. Rammohan RG, Welch RM, Paulson JA, Hiersch M, Jain A, Vassiliou AM, et al. Antigen recognition is facilitated by invadosome-like protrusions formed by memory/effector T cells. Proc Natl Acad Sci U S A 2013;110:6073–8.

137. Geiger B, Rosen D, Berke G. Spatial relationships of microtubule-organizing centers and the contact area of cytotoxic T lymphocytes and target cells. J Cell Biol 1982;95:137–43.

138. Kupfer A, Swain SL, Janeway CA Jr, Singer SJ. The specific direct interaction of helper T cells and antigen-presenting B cells. Proc Natl Acad Sci U S A 1986;83:6080–3.

139. Poo WJ, Conrad L, Janeway CA Jr. Receptor-directed focusing of lymphokine release by helper T cells. Nature 1988;332:378–80.

140. Huse M, Lillemeier BF, Kuhrs MS, Chen DS, Davis MM. T cells use multiple cytoskeletal mechanisms to develop lymphokine release and lytic function. Nat Immunol 2006;7:247–55.

141. Das V, Nat B, Dujeanocourt A, Thoublouze ML, Galli T, Roux P, et al. Activation-induced polarized recycling targets T cell antigen receptors to the immunological synapse: involvement of SNARE complexes. Immunity 2004;20:577–88.

142. Finetti F, Paccari SR, Riparbelli MG, Giacornello E, Perinetti G, Pazzou GJ, et al. Intraflagellar transport is required for polarized recycling of the TCR/CD3 complex to the immune synapse. Nat Cell Biol 2009;11:1332–9.

143. de la Roche M, Ritter AT, Angus KL, Dinsmore C, Earnshaw CH, Reiter ST, et al. Hedgehog signaling controls T cell killing at the immunological synapse. Science 2013;342:1247–50.

144. Bertrand F, Muller S, Roh KH, Laurent C, Dupre L, Valtuttii S. An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse. Proc Natl Acad Sci U S A 2013;110:6073–8.

145. Dequigne J, Breat B, Lemaitre F, Di Santo JP, Bousso P. Intravitral imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity 2010;33:632–44.

146. Dequigne J, Breat B, Lemaitre F, Bousso P. Cutting edge: tumor-targeting antibodies enhance NGF20-mediated NK cell cytotoxicity by stabilizing NK cell–tumor cell interactions. J Immunol 2012;189:5493–7.

147. Beal AM, Anikeeva N, Varma R, Cameron TO, Norris PJ, Dustin ML, et al. Protein kinase C{theta} regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by T. J Immunol 2008;181:4815–24.

148. Beal AM, Anikeeva N, Varma R, Cameron TO, Vasiliev-Shamis G, Norris PJ, et al. Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain. Immunity 2009;31:338–42.

149. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313:1972–5.

150. Martinez-Martín N, Fernandez-Arenas E, Cemerski S, Delgado P, Turner M, Heuser J, et al. T cell receptor internalization from the immunological synapse is mediated by TC21 and RhoG GTPase-dependent phagocytosis. Immunity 2011;35:208–22.

151. Huang JF, Yang Y, Sepulveda H, Shi W, Hwang J, Peterson PA, et al. TCR-mediated internalization of peptide–MHC complexes acquired by T cells. Science 1999;286:392–4.

152. Peters PJ, Geuze HJ, van der Donk HA, Slot JW, Griffith JM, Stamm NJ, et al. Molecules relevant for T cell-target cell interaction are present in cytolytic granules of human T lymphocytes. Eur J Immunol 1989;19:1469–75.

153. Peters PJ, Geuze HJ, van der Donk HA, Borst J. A new model for lethal hit delivery by cytotoxic T lymphocytes. Immunol Today 1990;11:28–32.
